Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo Positive about Changing Rules to Set Sales Thresholds after Market Expansion Re-Pricing Applied
November 11, 2019
- Japan to Use September 2019 Market Price Data for 2020 Revisions, April 2018 NHI Prices as Baseline
November 11, 2019
- LDP Lawmakers to Launch Group to Reinstate HPV Vaccine Recommendation
November 11, 2019
- Opposition Party Set to Compile HPV Vaccine Proposal by Year-End
November 8, 2019
- Substantive Diet Discussions Get Underway for PMD Law Amendment
November 7, 2019
- Zolgensma Not on Roster for Nov. 13 MHLW Panel Review
November 7, 2019
- Japan Industry Asks for AMED Funding of 50 Billion Yen to Build Big Data Platform
November 6, 2019
- Aso, CEFP Members Talked about Aducanumab at Oct. 28 Meeting, Minutes Reveal
November 6, 2019
- MOF Frets Financial Impact of Pricey Meds for Big Patient Populations, Cites Xolair’s Use in Pollen Allergy
November 5, 2019
- Australia Adds Japan to List of Countries Eligible for Expedited Review of New Drugs
November 5, 2019
- Key Japan Panel OKs Xolair as 1st Antibody Drug for Pollen Allergy
November 1, 2019
- MHLW Orders Label Revision for ADHD Treatment Concerta Based on New Distribution Control Policy
October 31, 2019
- Healthcare Providers Fret over Safety of Alternatives to Ranitidine amid Recalls
October 30, 2019
- PMDA Reviewing ILD Risks for Erleada, Xtandi
October 30, 2019
- MHLW Orders Label Revisions for Takecab to Include Pancytopenia to ADR List
October 30, 2019
- CEFP Members Prod Govt to Set Value-Based Target for Generic Promotion, but MHLW Wary
October 29, 2019
- Insurance Coverage of Cancer Genomic Profiling Tests in Early Stage Is Difficult: MHLW Official
October 29, 2019
- 1,419 ADR Victim Relief Claims Recieved in FY2018: MHLW
October 29, 2019
- 1st Topical JAK Inhibitor in Line for Japan Approval in January
October 28, 2019
- Decision on Whether Antibiotics Are Manufactured in Japan or Overseas Should be Left to Drug Makers: Govt
October 28, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…